• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    SC 13G/A 1 formsc13ga.htm FORM SC 13G/A WCM Investment Management: Form SC 13G/A - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

    ResMed Inc.

    (Name of Issuer)

     

    Common

    (Title of Class of Securities)

     

    761152107

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     [X]  Rule 13d-1(b)

     [_]  Rule 13d-1(c)

     [_]  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    SCHEDULE 13G

    CUSIP No.           761152107


    1

    Names of Reporting Persons

    WCM Investment Management, LLC

    2

    Check the appropriate box if a member of a Group (see instructions)

    (a)  [ ]
    (b)  [ ]

    3

    Sec Use Only

     

    4

    Citizenship or Place of Organization

    Delaware

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5

    Sole Voting Power

    3,832,642

    6

    Shared Voting Power

    0

    7

    Sole Dispositive Power

    3,832,642

    8

    Shared Dispositive Power

    0

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,832,642

    10

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    [ ]

    11

    Percent of class represented by amount in row (9)

    2.6%

    12

    Type of Reporting Person (See Instructions)

    IA


    Page 2 of 5


    Item 1.

    (a) Name of Issuer: ResMed Inc.

    (b) Address of Issuer's Principal Executive Offices: 9001 Spectrum Center Blvd, San Diego, CA 92123 United States

    Item 2.

    (a) Name of Person Filing: WCM Investment Management, LLC

    (b) Address of Principal Business Office or, if None, Residence:  281 Brooks Street, Laguna Beach, California 92651

    (c) Citizenship: Delaware

    (d) Title and Class of Securities: Common

    (e) CUSIP No.: 761152107

    Item 3.  If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [_] Broker or dealer registered under Section 15 of the Act;

    (b) [_] Bank as defined in Section 3(a)(6) of the Act;

    (c) [_] Insurance company as defined in Section 3(a)(19) of the Act;

    (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940;

    (e) [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

    (j) [_] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

    (k) [_] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Item 4. Ownership

    (a) Amount Beneficially Owned:  3,832,642

    Page 3 of 5


    (b) Percent of Class:  2.6%

    (c) Number of shares as to which such person has:

     (i) Sole power to vote or to direct the vote: 3,832,642

     (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 3,832,642

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [    ].

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Item 8. Identification and classification of members of the group.

    Item 9. Notice of Dissolution of Group.

    Item 10. Certifications.

    Page 4 of 5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 9, 2023

    /s/ Signature

    Name/Title David J. Joerger, Chief Compliance Officer

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

    Page 5 of 5


    Get the next $RMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    4/15/2026Overweight
    Analyst
    12/16/2025$275.00Outperform → Neutral
    Robert W. Baird
    9/18/2025$330.00Buy
    Citigroup
    9/2/2025Hold → Outperform
    CLSA
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    More analyst ratings

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on ResMed

    Analyst initiated coverage of ResMed with a rating of Overweight

    4/15/26 11:26:08 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded ResMed from Outperform to Neutral and set a new price target of $275.00

    12/16/25 8:57:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on ResMed with a new price target

    Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00

    9/18/25 8:44:39 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

    SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders. The acquisition expands Resmed's clinical sleep health portfolio into an adjacent area of significant unmet need — the treatment of Restless Legs Syndrome (RLS), the third most prevalent sleep disorder.1,2 For Noctrix Health, joining Resmed brings an opportunity to scale its innovation, expand patient access, and accelerate impact fo

    6/1/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference

    SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days. About ResmedResmed (

    5/19/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)

    4 - RESMED INC (0000943819) (Issuer)

    6/3/26 3:45:27 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    5/11/26 7:33:48 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Bloomer Aaron

    3 - RESMED INC (0000943819) (Issuer)

    5/4/26 6:05:55 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    SEC Filings

    View All

    SEC Form SD filed by ResMed Inc.

    SD - RESMED INC (0000943819) (Filer)

    5/26/26 4:30:09 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    4/30/26 4:10:25 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - RESMED INC (0000943819) (Filer)

    4/30/26 4:06:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Financials

    Live finance-specific insights

    View All

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

    Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%GAAP income from operations increased 17%; non-GAAP income from operations up 18%GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2026.

    4/30/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026

    SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com•Date:1:30 p.m. PT / 4:30 p.m. ET•Time:London, Thursday, April 30, 2026, 9:30 p.m. BST•International:Sydney, Friday, May 1, 2026, 6:30 a.m. AEST    Please note, Resmed does not use outside phone lines t

    4/1/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

    SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.  "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat

    4/30/26 4:10:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care